Company news
Netramark Holdings Inc (TSX:AIAI) news
Netramark Holdings Inc news releases on 6ix. Latest, Sep 10, 2026: Peer-Reviewed Study Published in MDPI's AI Journal Shows NetraAI Uncovers Clinical Trial…
Press releases & updates
Peer-Reviewed Study Published in MDPI's AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models
September 10, 2026
NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor
September 8, 2026
NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
September 1, 2026
NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
August 27, 2026
NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High
August 20, 2026
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
July 13, 2026
NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
July 9, 2026
NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
June 29, 2026
NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026
June 9, 2026
NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
May 20, 2026
NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
May 14, 2026
NetraMark Announces Change To Board Of Directors
May 7, 2026
NetraMark Holdings Inc. (AIAI) Opens the Market
May 5, 2026
NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
May 4, 2026
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
April 30, 2026
NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
April 22, 2026
Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
April 20, 2026
Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
April 9, 2026
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
March 25, 2026
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
March 19, 2026
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer's Trial at AD/PD Conference
March 19, 2026
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
March 11, 2026
NetraMark Closes Final Tranche of $3.5 Million Private Placement
February 19, 2026